
Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.

Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

More than 100 health care organizations signed a HHS climate resilience pledge; linking patients in addiction treatment with a primary care practitioner is linked with improved long-term health outcomes; older men and women with weak grip strength may have accelerated biological aging.

Genetic factors previously known to predispose people to hyperopia were not risk factors for clinically significant depression in the study.

The report, from the CDC, said that more than 3 million youth, or almost 1 in 9, reported using tobacco this year, and that disparities persist among US middle and high school students, with the highest rates among those who struggle in school or who have severe severe psychological distress.

A new study found that an imbalance of 2 placental proteins, serum soluble fms-like tyrosine kinase 1 and placental growth factor, could predict the risk of a severe form of preeclampsia.

This investigation involved analyses of the potential for pulmonary hypertension (PH) and interstitial lung disease (ILD) to have an impact on patients living with systemic sclerosis.

The hesitation to prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with hemophilia is not supported by current research, based on a recently published review, but the available studies had significant limitations.

Ishani Ganguli, MD, MPH, assistant professor of medicine at Harvard Medical School, physician at Brigham and Women’s Hospital, reacts to receiving the 2022 Seema S. Sonnad Emerging Leader in Managed Care Research Award.

Patients with intermediate and mild Parkinson disease, defined by a Hoehn & Yahr stage of 3 or less, experienced an additional deterioration in motor function with simvastatin compared with placebo while not taking medication at 24 months.

The increasing rate of melanoma diagnosis may not be due to actual disease, the authors of a new study posit; instead, it may be due to overdiagnosis of patients with an actual very low risk of death.

A study in Brazil found that delaying the start to the school day by an hour improved sleepiness and mood profile in children attending high school.

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center.

A listeria outbreak has been linked to deli meats and cheeses; the World Health Organization announced that there has been a 90% drop in recent deaths in COVID-19 globally compared with 9 months ago; Eli Lilly was ordered to pay $176.5 million in a US migraine drug patent trial.

Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated with fluids—more data are needed on outcomes following fluid administration.

Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.

This new report also shows the value of national databases tracking the use of ventilation support.

Patients with type 2 diabetes who use empagliflozin or sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2) long term were shown to have less kidney function loss.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor use in people with type 1 diabetes.

Although the understanding of chronic graft-versus-host disease (GVHD) has improved in recent years, more work is needed to facilitate personalized treatments for patients after hematopoietic stem cell transplantation (HSCT).

Several known risk factors and prodromal features were associated with Parkinson disease, including traumatic brain injury and alcohol misuse, along with other comorbidities such as skin and gastrointestinal disorders.

A new report has found continuous glucose monitoring (CGM) may help reduce staff burden in the intensive care unit (ICU) by reducing the need for blood gas monitoring.

The investigators of a new study evaluated if nasal cytology was a reliable method to identify type 2 inflammation in patients who have chronic rhinosinusitis with nasal polyps (CRSwNP), which could then facilitate patient selection for biological drug utilization via endotypization.

An analysis of Medicaid coverage found that Mississippi was the only state not to provide coverage for human papillomavirus (HPV) vaccination in adults aged 27 to 45 years.

Abortion rights measures on the ballot saw victories in all 5 states; South Dakota voted to expand access to Medicaid; rates of inflammatory heart conditions were increased in people with the second dose of the Moderna COVID-19 vaccine.

A study found that the characteristics and location of epilepsy centers in the United States are associated with differences in presurgical testing for drug-0resistant epilepsy.

The new data suggest risdiplam can be a viable option for people with spinal muscular atrophy who cannot take or tolerate the 2 other approved disease-modifying therapies.

The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

Zanubrutinib is the latest of 3 Bruton tyrosine kinase (BTK) inhibitors approved for rare B-cell malignancies, such as Waldenström macroglobulinemia, a non-Hodgkin B-cell lymphoma (NHBCL); as a next-generation BTK inhibitor, zanubrutinib is designed to have less off-target effects.

While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.